Company Overview and News

Review finds airports charge you too much

Australians are being gouged by under-regulated monopolistic airports abusing their market power, according to former competition watchdog boss Graeme Samuel.

Shares up as Comvita, A2 rebound from weakness, Steel & Tube keeps dropping

New Zealand shares gained as Comvita and A2 Milk Co recovered from selling, while Air New Zealand and Steel & Tube Holdings fell.

This is how much airlines bump up ticket prices on their busiest days

New figures have revealed just how much Australian travellers are slugged to fly on the busiest days of the year, with our two full-service airlines more than doubling average fares around major sporting events and New Year's Eve.

This is how much airlines bump up ticket prices on their busiest days

New figures have revealed just how much Australian travellers are slugged to fly on the busiest days of the year, with our two full-service airlines more than doubling average fares around major sporting events and New Year's Eve.

Winter warmers: Why air deals to Bali are heating up

Emirates is banking on its new Bali route being popular with surfers by carrying boards for free on a route that is shaping up as a hotly contested one as Air New Zealand faces competition on direct services for the first time.

Air New Zealand to feel brunt of rising fuel prices on international routes, analysts say

Air New Zealand's international routes will bear the brunt of oil prices near a 3 and a half year high as stiffer competition and the cost of flying vast distances set a higher bar for the national carrier than the domestic market, analysts say.

Air New Zealand slashes the price of its in-flight Wi-Fi by 25 per cent

When it was introduced about 10 days ago the price was $40 a sector but today the airline said today it had now been cut.

Would you pay $40 a sector for Air New Zealand's inflight Wi-Fi

Air New Zealand passengers will be able to access Wi-Fi on international flights — for a chunky price.

Royal treatment: How Air NZ passengers can cash in on Meghan and Harry's big day

Air New Zealand will celebrate the royal wedding of Prince Harry and Meghan Markle by offering free lounge access to passengers who share the same wedding date.

Blackstone strikes $635m 7-block Auckland office deal: Air NZ and Fonterra HQ to be sold

Blackstone funds have struck a $635 million deal to buy seven big central Auckland office blocks, subject to Overseas Investment Office and land owner approval, the vendor has announced.

Battle of Business Class: The high stakes relaunch for Air New Zealand

Just over 5 per cent of passengers fly business class or better but they provide nearly a third of annual global revenue for airlines which totals $1.1 trillion.

A seismic exchange of strategy

Last year there was just one initial public offering on the New Zealand Stock Exchange's main board versus eight de-listings — despite the local sharemarket having otherwise enjoyed a record-breaking 12 months.

Time to reconvene Capital Markets Taskforce?

It's time to reconvene the Capital Markets Taskforce and have a clear look at whether more state assets can be primed for partial privatisation through the mixed-ownership model (MOM) and beef up liquidity at the NZX.

Air New Zealand eyes return to Wānaka and commits to current regional routes

Air New Zealand is considering restoring flights to Wānaka as part of a plan to grow its regional network by 20 per cent during the next five years.

MARKET WRAP: MSCI index reshuffle - the winners and losers

An MSCI index reshuffle sent shares for Fletcher Building soaring after it survived, but Mercury Energy shares fell as it was culled from the index.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...